SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ADEMPAS

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since October 2013. First generic entered the US market on October 5, 2026.
Why 3/10
ADEMPAS is already approved and commercialized with no pending regulatory decision or pivotal readout. The next material event was the first generic launch on October 5, 2026, which has already occurred. No hard dated binary catalyst is scheduled in the next ~12 months.
Actionable Insight NEUTRAL

The first generic riociguat launched on October 5, 2026, which will erode Adempas sales and Merck's alliance revenue share over time. Merck reports Adempas/Verquvo alliance revenue as a combined line item in its quarterly filings; watch for declining contributions in upcoming earnings. No binary catalysts remain for this mature, approved drug.

Price Chart

Loading chart...

Executive Summary

ADEMPAS (riociguat) is an FDA-approved oral drug for two forms of pulmonary hypertension, developed and primarily marketed by Bayer AG. Merck & Co. (MRK) has a financial interest through a 2014 worldwide collaboration with Bayer, under which Merck receives a share of profits from Adempas and Verquvo sales in Bayer's territories. Adempas generated approximately EUR 745 million (~USD 850 million) in global sales in 2025. On October 5, 2026, Zydus/MSN launched the first generic riociguat in the US, following the loss of US patent protection. For Merck, Adempas alliance revenue is a very small component (combined with Verquvo at ~$126 million in Q2 2025) of a $65 billion revenue base, making this drug a negligible driver for MRK stock.

How It Works

Riociguat is a soluble guanylate cyclase (sGC) stimulator. It works by helping blood vessels relax and widen, which lowers blood pressure in the lungs and improves the heart's ability to pump blood. It is taken as an oral tablet.

Trial Status

ADEMPAS was FDA-approved on October 8, 2013, for two indications: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4). It is a commercially marketed product. A Phase 2 trial in pulmonary hypertension with left ventricular systolic dysfunction was terminated. No pivotal trials are ongoing.

The Two-Sided Case

▲ Bull Case4
Adempas generated approximately EUR 745 million (USD ~$850 million) in global sales in 2025, up from EUR 721 million in 2024, showing continued growth before generic entry.
Adempas remains the only FDA-approved drug for chronic thromboembolic pulmonary hypertension (CTEPH), a protected indication that may slow generic erosion.
Merck's collaboration with Bayer gives it a share of profits from Adempas and Verquvo sales with no development cost exposure, providing low-risk alliance revenue.
Merck is a $347 billion market-cap diversified pharma giant with 26 analysts rating it Buy/Strong Buy, and the stock has returned ~60% over the past year.
▼ Bear Case4
First generic riociguat launched in the US on October 5, 2026, by Zydus/MSN, which will erode Adempas market share and pricing power.
Adempas lost US patent protection in 2026, opening the door to additional generic entrants and accelerating revenue decline.
Merck's alliance revenue from Adempas/Verquvo was only $126 million in Q2 2025 (combined), a tiny fraction of Merck's $65 billion in total 2025 revenue, so any erosion has negligible impact on MRK stock.
The drug faces competition from other PAH/CTEPH therapies including newer classes of treatments.

Upcoming Catalysts

  • No binary catalysts remain for this approved, mature drug. The key recent event was the first generic launch on October 5, 2026. Watch for quarterly alliance revenue declines in Merck's earnings reports as generic competition takes effect.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 drugs.com3 prnewswire.com4 pharma.economictimes.indiatimes.com5 merck.com6 sec.gov7 stocktitan.net8 reports.bayer.com9 regulatorynews.com10 merck.com11 app.edgar.tools